The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2022

Filed:

Aug. 16, 2017
Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

The General Hospital Corporation, Boston, MA (US);

Inventors:

Edward Holson, Newton, MA (US);

Florence Fevrier Wagner, Ashland, MA (US);

Stephen J. Haggarty, Gloucester, MA (US);

Yan-Ling Zhang, Lexington, MA (US);

Morten Lundh, Copenhagen, DK;

Bridget Wagner, Medford, MA (US);

Michael C. Lewis, Boston, MA (US);

Tracey Lynn Petryshen, Arlington, MA (US);

Assignees:

The Broad Institute, Inc., Cambridge, MA (US);

The General Hospital Corporation, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 233/80 (2006.01); C07C 237/40 (2006.01); C07C 237/42 (2006.01); C07D 213/38 (2006.01); C07D 239/42 (2006.01); A61K 31/13 (2006.01); A61K 31/155 (2006.01); A61K 31/167 (2006.01); A61K 31/4406 (2006.01); A61K 31/4439 (2006.01); A61K 31/445 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/55 (2006.01); A61K 38/26 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 213/38 (2013.01); A61K 31/13 (2013.01); A61K 31/155 (2013.01); A61K 31/167 (2013.01); A61K 31/445 (2013.01); A61K 31/4406 (2013.01); A61K 31/4439 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/55 (2013.01); A61K 38/26 (2013.01); A61K 45/06 (2013.01); C07C 233/80 (2013.01); C07C 237/40 (2013.01); C07C 237/42 (2013.01); C07D 239/42 (2013.01);
Abstract

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X, X, X, X, X, W, W, W, and Ware as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.


Find Patent Forward Citations

Loading…